Allergy Therapeutics plc (LON:AGY) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $13.16 and traded as low as $13.50. Allergy Therapeutics shares last traded at $13.86, with a volume of 328,732 shares.
Several equities research analysts recently commented on AGY shares. FinnCap reissued a “corporate” rating on shares of Allergy Therapeutics in a report on Wednesday, March 6th. Numis Securities reissued a “buy” rating and issued a GBX 45 ($0.59) price target on shares of Allergy Therapeutics in a report on Wednesday, March 6th.
The company has a debt-to-equity ratio of 6.20, a quick ratio of 3.08 and a current ratio of 3.74. The business has a 50 day simple moving average of GBX 13.32. The firm has a market capitalization of $89.06 million and a P/E ratio of -28.00.
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
Read More: What is a Tariff?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.